The ability of dopamine D 4 and D 2 receptors to activate extracellular signal-regulated kinases (ERKs) 1 and 2 was compared using Chinese hamster ovary (CHO-K1) cells transfected with ABBREVIATIONS: MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; CHO, Chinese hamster ovary; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; Sos, son of sevenless guanine nucleotide exchange factor; MEK, mitogenactivated protein kinase/extracellular signal-regulated kinase kinase; Ras, rat sarcoma virus p21 GTPase; Pyk2, proline-rich tyrosine kinase; PI3-kinase, phosphoinositide 3-kinase; PKC, protein kinase C; MEM, minimal essential medium; HRP, horseradish peroxidase; tyrphostin A9, [[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-methylene]propanedinitrile; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid acetoxymethyl ester; PP2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-day-]pyrimidine; HA, hemagglutinin; DTT, dithiothreitol; PAGE, polyacrylamide gel electrophoresis; TBS, Tris-buffered saline; MBP, myelin basic protein; haD 2 , HA epitope-tagged dopamine D 2 receptor; haD 4 , HA epitope-tagged dopamine D 4 receptor; ␤ARK1ct, ␤-adrenergic receptor kinase 1 carboxyl terminus; PTX, pertussis toxin; DMSO, dimethyl sulfoxide; PDGFR␤, platelet-derived growth factor receptor-␤; PLC, phospholipase C; Shc, SH2-containing adapter protein.
Dopamine is the predominant catecholamine neurotransmitter in the central nervous system and is involved in neurological and psychiatric disorders, including Parkinson's disease, Tourette's syndrome and schizophrenia. The D 2 -like dopamine receptors (including D 2 , D 3 and D 4 ) share a high affinity for antipsychotic drugs and couple through pertussis toxin-sensitive G proteins (G i/o ). Functionally, all D 2 -like receptors have been shown to inhibit adenylyl cyclase, stimulate the Na ϩ /H ϩ antiporter, activate K ϩ -channels, produce Cl -influx, alter neural morphology and stimulate mitogenesis. Additional intracellular effects of D 2 or D 4 receptors include arachidonic acid release, phosphoinositide hydrolysis, Ca 2ϩ -channel inhibition and apoptosis. It is now established that numerous G protein-coupled receptors can also activate mitogen-activated protein kinases (MAPKs), such as p38, ERK, and c-Jun NH 2 -terminal kinase (Gutkind, 1998) . The mitogenic potential of dopamine D 2 -like receptors was recognized by Lajiness et al. (1993) , who observed that the D 2 receptor could stimulate [
3 H]thymidine incorporation in CHO cells by a mechanism that was independent of cAMP inhibition but sensitive to the G i/o -inactivator pertussis toxin and the tyrosine kinase inhibitor genistein. This effect was later observed with D 3 and D 4 receptors as well (Lajiness et al., 1995; Pilon et al., 1994) . These reports were in contrast to studies with pituitary tumor tissue and cell lines, where the D 2 receptor was found to have an antiproliferative role (Florio et al., 1992) and reduced thyrotropin-releasing hormone-induced MAPK activation (Ohmichi et al., 1994) . In neuronal MN9D cells, D 2 , D 3 , and D 4 receptors were shown to alter neural morphology (Swarzenski et al., 1994) , whereas others reported both apoptosis and differentiation as a result of D 2 receptor signaling in neuronal cells (Coronas et al., 1997) . A unifying element of these effects may be MAPK pathways, which are capable of mediating diverse cellular actions. Recent studies have reported that dopamine D 2 , D 3 , and D 4 receptors can independently stimulate the activity of the MAPKs ERK1/2 or c-Jun NH 2 -terminal kinase (Luo et al., 1998; Oldenhof et al., 1998; Welsh et al., 1998; Cussac et al., 1999) .
The MAPKs are a group of serine/threonine kinases that are activated by a cascade of protein kinases to induce responses such as proliferation, differentiation, apoptosis, and long-term potentiation. Classically, activation of MAPK pathways have been attributed to the activity of growth factor receptors. Binding of growth factors such as EGF or PDGF to receptor tyrosine kinases results in receptor dimerization and autophosphorylation. Binding of Grb2 (either directly or via other adapter proteins) to activated growth factor receptors promotes translocation of the Grb2-associated protein Sos to the membrane. The guanine nucleotide exchange factor Sos catalyzes the activation of Ras by promoting GTP/GDP exchange. Ras participates in the activation of the cytosolic serine/threonine kinase Raf-1 (MAPK kinase kinase), which activates MEK1/2 (MAPK kinase) and ultimately stimulation of ERK1/2. Activated ERK1/2 can phosphorylate cytosolic substrates and is translocated to the nucleus, leading to the activation transcription factors.
Among G i/o -coupled receptors, activation of MAPK has been attributed to both G␣ and G␤␥, and the mechanism of activation can differ among specific G i/o -coupled receptors and cell lines. Some G protein-coupled receptors seem to activate MAPK by trans-activation of a receptor tyrosine kinase such as the EGF receptor (Daub et al., 1996) . Once trans-activated by an as-yet poorly defined mechanism, these receptors can recruit effectors, such as the Shc/Grb2/Sos pathway of Ras activation, to stimulate MAPK. The Ca 2ϩ -dependent kinase Pyk2 (related focal adhesion tyrosine kinase) has been identified as a component of the G i/o -coupled receptor pathway to ERK activation (Dikic et al., 1996) . Rasindependent mechanisms of MAPK activation by G i -coupled receptors have also been described. In CHO cells, G i -coupled lysophosphatidic acid receptors seem to signal through PI3-kinase␥/PKC to activate MEK in a manner that is unaffected by dominant negative Sos (Takeda et al., 1999 
Materials and Methods
Reagents. CHO-K1 cells were purchased from American Type Culture Collection (Manassas, VA). ␣-MEM was purchased from Central Media Preparation Service (University of Toronto, Toronto, ON, Canada). Fetal bovine serum, horse serum, Geneticin (G418), T4 DNA ligase, T4 polynucleotide kinase, sequencing oligonucleotides and myelin basic protein were bought from Invitrogen (Carlsbad, CA). All restriction endonucleases, calf intestinal alkaline phosphatase, rabbit polyclonal anti-phosphoERK(Tyr204), mouse monoclonal anti-phosphoERK E10 (Thr202/Tyr204), rabbit polyclonal anti-phosphoElk1 (Ser383) and anti-rabbit-HRP were obtained from New England BioLabs (Beverly, MA [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one], GF109203X (bisindolylmaleimide I), 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2), Gö 6976, and Calphostin C were from Calbiochem (San Diego, CA). Rabbit anti-ERK1 (C-16), rabbit anti-ERK2 (C-14), and rabbit polyclonal anti-PDGFR␤ (958) were acquired from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal mouse anti-phosphotyrosine antibody (4G10) was from Upstate Biotechnology (Lake Placid, NY). D 4 and D 2 Plasmid Constructs. The vector pcDNA3 (Invitrogen) containing the dopamine D 2L or D 4 receptor cDNA with an amino-terminal, cleavable signal sequence (MKTIIALSYIFCLVFA) and the hemagglutinin (HA) epitope (DYPYDVPDYA), were produced by Dr. R. Vickery (University of California at San Francisco). D 2L was excised from pcDNAI by a blunted NcoI/XhoI digest. The plasmid pBCSSHA␦ was digested with BamHI to excise the ␦-opioid receptor. After blunting the vector and a XhoI digest, the D 2 sequence was inserted to create pBCSSHAD2L. The modified D 2L receptor was removed from pBC with a HindIII/XhoI digest and subcloned into pcDNA3 to produce pcSSHAD2L. Using a partial NcoI/BamHI digest, the dopamine D 4.7 receptor was cut from pBD4.7 (Asghari et al., 1994) and cloned into the NcoI/BamHI site of pBC-SSHA␦ to create pBCSSHAD4.7. The tagged D 4 receptor was cut with HindIII/BamHI from pBCSSHAD4.7 and subcloned into pcDNA3. Partial NotI/XbaI digest of the D 4.2 and D 4.4 receptors in pBluescript (Asghari et al., 1994) resulted in 1.2-and 1.3-kilobase pair fragments that were ligated into pcSSHAD4.7 at NotI/XbaI to produce pcSSHAD4.2 and pcSSHAD4.4.
Cell Culture. Cells were grown in supplemented ␣-MEM media (2.5% fetal bovine serum and 2.5% horse serum) as monolayers at 37°C in a humidified, 5% CO 2 atmosphere. Stable CHO-K1 cell lines of pcDNA3 (vector control), pcSSHAD4.2, pcSSHAD4.4, pc-SSHAD4.7, and pcSSHAD2L were transfected by electroporation as described previously (Asghari et al., 1995) . Transient transfections and stable transfection of pBK-PDGFR␤ were carried out with LipofectAMINE reagent (Invitrogen) as described by the manufacturer. Individual CHO-K1 clones were grown in media containing 500 g/ml G418.
Radioligand Binding. Cells were resuspended in binding buffer (120 mM NaCl, 50 mM Tris-HCl, 5 mM KCl, 5 mM MgCl 2 ,1.5 mM CaCl 2, 0.5 mM EDTA, pH 7.4) and mechanically homogenized (Pro Scientific Inc., Monroe, CT; maximum, 15 s, on ice). Cell membranes were pelleted by centrifugation (34,000g for 20 min at 4°C) and 
where X is the total amount of ligand (disintegrations per minute), Y is the total binding (disintegrations per minute), and NS is the nonspecific binding constant. NS was determined experimentally by coincubating with 1 M haloperidol and fitting the data to the equation Y ϭ X ϫ [NS / (NS ϩ 1)]. Protein concentration was determined using the bicinchoninic acid assay (Pierce, Rockford, IL) .
cAMP Assay. Cells stably expressing receptors were plated on six-well plates and grown to ϳ80% confluence. Cells were treated with 1 M dopamine and the cAMP concentration in the lysate was determined by [
125 I]cAMP radioimmunoassay as described previously (Asghari et al., 1995) using a standard curve fit to a sigmoidal
where X is the logarithm of the concentration, Y is the response, and n H is the Hill slope] using GraphPad Prism v2.0.
MAPK Assay. Cells were plated on six-well plates, grown to ϳ80% confluence, rinsed with serum-free ␣-MEM and incubated overnight in serum-free ␣-MEM. Cells were preincubated with various drugs before activation with 1 M dopamine/quinpirole or 10 ng/ml PDGF-BB. Drug incubation was ended by washing the cells with 2 ml of ice-cold PBS followed by the addition of either 250 l of lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5% sodium pyrophosphate, 1 mM ␤-glycerolphosphate, 1 mM sodium orthovanadate, 1 g/ml leupeptin, 1 g/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride) for Elk or MBP kinase assays or 100 to 200 l of sample buffer [62.5 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% glycerol, 50 mM DTT, and 0.1% (w/v) bromphenol blue] to assay the phosphorylation state of ERK1/2. ERK1/2 activity was determined using a MAP kinase assay kit by New England Biolabs. Lysates were incubated for 5 min on ice, scraped, sonicated (4 ϫ 5 s) and centrifuged (14,000 rpm for 10 min at 4°C). To immunoprecipitate active ERK1/2, 4 l of rabbit polyclonal anti-phospho-MAPK antibody was added to 200 l of the cleared lysate and incubated overnight at 4°C. Protein A-Sepharose [25 l at 50% (v/v)] was added and the lysate was incubated for 2 h at 4°C. After washing twice with 500 l of lysis buffer and twice with 500 l of Elk kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM ␤-glycerolphosphate, 2 mM DTT, 0.1 mM sodium orthovanadate, and 10 mM MgCl 2 ); beads were resuspended in 50 l of Elk kinase buffer containing 0.1 mM ATP and 1 g of Elk1-GST fusion protein and incubated at 30°C for 30 min. The reaction was stopped by addition of 25 l of 3ϫ sample buffer, denatured (95°C for 5 min), microcentrifuged for 2 min and separated by 10% SDS-PAGE gel (Novex, San Diego, CA). After electrophoresis, proteins were transferred from the gel to a polyvinylidene difluoride membrane (Novex). The membrane was incubated for 2 h in blocking buffer [TBS (20 mM Tris-HCl, 137 mM NaCl, pH 7.6) and 0.1% Tween-20, 5% nonfat dry milk, and 0.02% NaN 3 ] and probed overnight with anti-phospho-Elk1 (1:1000 in blocking buffer) at 4°C. After washing three times with TBS-T (TBS with 0.1% Tween-20) for 5 min, the blot was probed with peroxidase-conjugated secondary antibody (1:2000 anti-rabbit-HRP in blocking buffer without NaN 3 ) for 1 h at room temperature. The membrane was washed three times with TBS-T for 5 min and phosphorylated Elk1 was detected by enhanced chemiluminescence with ECLϩplus (Amersham Pharmacia Biotech, Oakville, ON).
ERK1/2 activity was also measured by the in vitro phosphorylation of myelin basic protein (MBP). Cleared cell lysates (see above) were incubated overnight with 1:100 dilutions of anti-ERK1 (C-16) and anti-ERK2 (C-14). After collection with protein-A Sepharose, the beads were washed twice with lysis buffer and twice with MBP kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl 2 , and 1 mM DTT). Beads were resuspended in 50 l of MBP kinase buffer containing 12.5 g of myelin basic protein, 2 Ci of [␥-32 P]ATP, and 20 M unlabeled ATP and incubated at 30°C for 20 min. A 10-l aliquot was spotted onto P81 phosphocellulose filter paper (Whatman), washed with cold 0.5% phosphoric acid (5 ϫ 5 min), rinsed with ethanol and dried. The incorporation of 32 P into myelin basic protein was measured by liquid scintillation counting.
To detect phosphorylated forms of ERK1/2, cells were scraped after addition of sample buffer, sonicated for 20 s and denatured (95°C for 5 min). Samples were microcentrifuged for 5 min, and 20 l was loaded onto an 8 to 16% Tris-glycine gel. After SDS-PAGE, Western blotting, and blocking, the polyvinylidene difluoride membranes were incubated with mouse monoclonal anti-phospho-MAPK E10 (Thr202/Tyr204) (1:1000 in blocking buffer). The blots were incubated 1 to 2 h at room temperature, washed with TBS-T (4 ϫ 5 min), and subsequently incubated for 1 h with anti-mouse-HRP (1:4000 blocking buffer without NaN 3 ) at room temperature. Membranes were washed with TBS-T (4 ϫ 5 min) and the phosphorylated forms of ERK1 and ERK2 were detected by chemiluminescence.
Western Blotting of Phosphorylated PDGFR␤. CHO-K1 cells stably expressing PDGF receptor-␤ were transiently transfected with pcSSHAD4.4 and/or treated with drugs and cell lysates were prepared as described previously (Domin et al., 1996) . Receptors were immunoprecipitated by incubating with 1 g of anti-PDGFR-␤ (3 h at 4°C) followed by addition of 20 l of 50% protein A-Sepharose (3 h at 4°C). After washing three times with lysis buffer, pelleted beads were resuspended in sample buffer and denatured (95°C for 2 min). Immunoprecipitated proteins were separated with a 4 to 12% SDS-PAGE gel and Western blotting was carried out using antiphosphotyrosine (1 g/ml)/anti-mouse-HRP (1:8000).
Results

CHO-K1 Cell Lines Expressing HA-tagged D 4 or D 2L
Receptors. Wild-type human dopamine D 4.2 , D 4.4 , D 4.7 , and D 2L receptors were modified by the addition of a cleavable, membrane-targeted signal sequence and an amino terminal HA-epitope tag. Clonal CHO-K1 cell lines expressing 0.78 to 1.6 pmol of receptor/mg of membrane protein were selected (Table 1 ). All cell lines except the control CHO-pcDNA3 inhibited forskolin-stimulated cAMP in response to 1 M dopamine (Fig. 1) .
Activation of ERK1/2 by haD 4 and haD 2L Receptors. To determine whether various polymorphic variants of the dopamine D 4 receptor can stimulate the MAPK pathway, the (Fig. 2B) , whereas the total level of ERK1/2 was unaffected (Fig. 2C) . Dopamine stimulation of ERK1/2 phosphorylation and activity was transient, with ERK kinase activity returning to basal levels by 30 min (Fig. 3B) , whereas residual ERK2 phosphorylation was still observable after 60 min (Fig. 3A) . The three polymorphic variants of the dopamine D 4 receptor and the D 2L receptor all displayed a similar pattern of transient ERK activation. Dopamine stimulation of CHO-haD4.4 and CHO-haD2L cells (1 M for 5 min) produced increases of 355 Ϯ 71% (mean Ϯ S.D., n ϭ 12) and 330 Ϯ 105% (n ϭ 13), respectively, in the activity of ERK1/2 as measured by in vitro myelin basic protein kinase activity compared with unstimulated cells.
A dose-response curve of MAPK activation by dopamine in CHO-haD4.4 and CHO-haD2L cells produced EC 50 values of 9 and 10 nM (Fig. 4) . Dopamine receptor-specific stimulation of ERK activity was confirmed using the D 2 -like receptorselective drugs quinpirole and haloperidol. The agonist quinpirole (1 M) produced a stimulation in ERK activity, and pretreatment of cells for 5 min with the antagonist haloperidol (1-5 M) abolished dopamine-stimulated ERK activity in CHO-haD2L cells and significantly reduced the activity of this kinase in cells expressing haD 4.4 receptors (Fig. 5) . (Fig. 6, A and B) . Both pertussis toxin and PD98059 abolished ERK activation by dopamine.
To further characterize the pathway, wild-type CHO-K1 cells were transiently cotransfected with pcSSHAD4.4 or pcSSHAD2L along with the dominant negative constructs ␤ARK1ct or RasN17 (Fig. 7) . Coexpression of ␤ARK1ct and RasN17 significantly attenuated the activation of ERK by haD 4 . Coexpression of haD 2L with RasN17 also reduced ERK activation, whereas ␤ARK1ct did not show a statistically significant effect. The effect of haD 4 and haD 2L receptors on ERK activity was independent of cellular cAMP levels, because pretreatment of cells with 8 bromo-cAMP (0.01 to 1 mM) did not block activation of this MAPK pathway (data not shown).
Inhibitors of PKC and PI3-Kinase Block Activation of ERK. To determine whether ERK activation by D 4 and D 2L receptors is dependent on PKC, CHO-haD4.4 and CHOhaD2L cells were preincubated with the PKC inhibitors GF109203X (bisindolylmaleimide I) (2 M), Gö 6976 (2 M), or Calphostin C (1 M) (Fig. 8) . MAPK activation by both haD 4 and haD 2L receptors was sensitive to the broad spectrum PKC inhibitors GF109203X and Calphostin C, but was not reduced by Gö 6976, which is selective for PKC␣-and PKC␤I. Pretreatment of cells with the PI3-kinase inhibitors wortmannin (1 M) and LY294002 (30 M) also blocked Ͼ50% of ERK stimulation by dopamine (Fig. 9) . receptors. Stably transfected CHO-pcDNA3 (control), CHO-haD4.2, CHO-haD4.4, CHO-haD4.7, and CHO-haD2L cells were treated with 10 M forskolin to activate adenylyl cyclase and stimulate cAMP levels. Cells were treated with dopamine (1 M) for 15 min before collecting cell lysates, and the cAMP level was measured using a cAMP radioimmunoassay as described under Materials and Methods. The results were normalized by setting forskolin-stimulated cAMP levels at 100% and represent the mean Ϯ S.D. for three to five independent experiments. Groups that show a significant difference in intracellular cAMP levels because of dopamine using a paired t test: *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001. MAPK catalytic activity was measured by a kinase assay using a recombinant MAPK substrate, Elk-1-GST. Phosphorylated Elk-1 was detected by Western blotting with anti-phosphoElk-1/anti-rabbit-HRP antibodies. B, phosphorylation of ERK1/2 after dopamine treatment. Phosphorylated MAPK was detected directly from cell lysates by Western blotting with anti-phospho-MAPK(Thr202/Tyr204)/anti-mouse IgG-HRP. C, total ERK1/ ERK2 levels in unstimulated and stimulated CHO cells. Total (i.e., unphosphorylated ϩ phosphorylated) ERK1/2 was measured in cell lysates by Western blotting with anti-p44/p42 MAPK antibody/anti-rabbit IgG-HRP. Western blots are from one of three independent experiments that produced similar results. mediated ERK1/2 phosphorylation (Fig. 10A ). This observation was confirmed by an in vitro kinase assay, where it was found that BAPTA-AM was only effective at concentrations above 10 M (Fig. 10B) . ERK Activation by Dopamine Is Dependent on PDGF Receptor trans-Activation. To test whether growth factor receptor signaling is recruited by dopamine D 4 and D 2L receptor MAPK signaling, cells were preincubated with the selective receptor tyrosine kinase inhibitors AG1478 (EGF receptor), tyrphostin A9 (PDGF receptor), and AG1295 (PDGF receptor). Although AG1478 (1 M) had no effect on dopamine-stimulated ERK phosphorylation, tyrphostin A9 pretreatment (1 M) eliminated the response of ERK to dopamine (Fig. 11A) . The in vitro kinase assay confirmed that both tyrphostin A9 and a second PDGF receptor tyrosine kinase inhibitor, AG1295 (10 M) potently blocked ERK stimulation by both haD 4.4 and haD 2L receptors in CHO-K1 cells (Fig. 11, B and C) . 4 . Dose-response of MAPK activation by dopamine. A, serum-deprived CHO-haD4.2 cells were treated with dopamine (1 pM to 100 M) for 5 min. After drug incubation, phospho-MAPK (Thr202/Tyr204) level was measured in cell lysates by Western blotting. B, stimulation of ERK1/2 kinase activity in response to dopamine. After treating serumdeprived CHO-haD4.4 (f) and CHO-haD2L (OE) with dopamine (10 pM to 10 M) for 5 min, ERK1/2 was immunoprecipitated, and their activity was quantified with an in vitro kinase assay using MBP as a substrate. ERK1/2 kinase activity was normalized by setting unstimulated activity at 0% and dopamine-stimulated activity at 100%. Data are presented as mean Ϯ S.D. (n ϭ 3). The EC 50 value for dopamine was determined by fitting the data to a sigmoidal dose-response curve using Prism (v. 2.0; GraphPad Software, San Diego, CA).
Oak et al.
Transient transfection of CHO-PDGFR␤ cells (stably expressing an increased level of PDGF receptor-␤) with pc-SSHAD4.4 followed by treatment with dopamine (1 M for 1-5 min) produced an immediate increase in the tyrosine phosphorylation of PDGF receptor-␤ (Fig. 12) , confirming that dopamine receptors can trans-activate this receptor tyrosine kinase.
The Src-family tyrosine kinase inhibitor PP2 (50 M) was also found to block ERK activation in response to dopamine (Fig. 13) . When PDGF-BB was tested on wild-type CHO-K1 cells, we found that pretreatment with tyrphostin A9, AG1295, and PP2 blocked ERK activation by endogenous PDGF receptor-␤ (Fig. 14A) . In addition, PP2 also strongly suppressed PDGF receptor-␤ autophosphorylation in response to PDGF-BB (Fig. 14B) . (Asghari et al., 1995; Guiramand et al., 1995) .
Discussion
ERK activation by both D 4 and D 2L receptors required a PTX-sensitive G protein (G i/o ), whereas sequestering G␤␥ with ␤ARK1ct peptide significantly attenuated ERK activation by the D 4 receptor. Activation of the ERK MAPK pathway by dopamine D 2S , D 2L , and D 3 receptors has previously been attributed to PTX-sensitive G proteins (Cussac et al., 1999; Luo et al., 1998) . The dominant-negative mutant RasN17 and the MEK inhibitor PD98059 also reduced or eliminated activation of ERK by both D 4 and D 2L receptors, suggesting that dopamine activates the Ras 3 Raf 3 MEK 3 ERK pathway.
Because it has emerged that G protein-coupled receptors can recruit growth factor receptors to facilitate MAPK signaling (Daub et al., 1996) , we tested selective inhibitors of EGF receptor and PDGF receptor tyrosine kinase activity. Although EGF receptor-selective AG1478 failed to block dopamine-stimulated ERK phosphorylation, PDGF receptorselective tyrphostin A9 and AG1295 potently inhibited ERK phosphorylation and kinase activity, indicating that this receptor tyrosine kinase is a required intermediate. CHO-K1 cells are known to endogenously express a low level of the PDGF receptor-␤ (Duckworth and Cantley, 1997) , and the PDGF receptor can act as a scaffold for numerous other kinases and adapter proteins, including Src, SH2 domaincontaining phosphotyrosine phosphatase-2, Shc, Grb2/Sos, PLC-␥, PI3-kinase, and Ras-GAP (reviewed by Heldin et al., 1998) . The role of trans-activation is supported by a rapid increase in tyrosine phosphorylation of PDGF receptor-␤ upon stimulation of the D 4.4 receptor, demonstrating that activation of the growth factor receptor occurs in a timeframe consistent with its involvement in MAPK signaling by dopamine.
The Src-family tyrosine kinase inhibitor PP2 blocked the activation of MAPK by dopamine and PDGF receptor-␤. PP2 also inhibited PDGF-BB-stimulated autophosphorylation of PDGF receptors overexpressed in CHO-K1 cells. These results are in agreement with a recent report by Waltenberger et al. (1999) that indicated that PP1, a Src-family kinase inhibitor closely related to PP2, inhibits the tyrosine kinase molpharm.aspetjournals.org activity of the PDGF receptor-␤ but did not block activation of EGF, fibroblast growth factor-1, or insulin-like growth factor-1 receptors. Conversely, tyrphostin A9 blocks Src kinase activity only partially at a concentration of 10 M (Lakkakorpi et al., 2000) , whereas AG1296, a less hydrophobic analog of AG1295, does not inhibit the kinase activity of Src (Kovalenko et al., 1994) . Therefore, it seems that the Src kinase inhibitor PP2 acts at the PDGF receptor-␤ to block MAPK activation by both dopamine and PDGF-BB.
Nonselective PKC inhibitors and the Ca 2ϩ -chelator BAPTA-AM (100 M) also abolished MAPK activation. CHO-K1 cells are known to possess PKC␣, ␥, ␦, ⑀, and isotypes (Tippmer et al., 1994; Shirai et al., 2000) . Cussac et al. (1999) proposed that an atypical PKC, PKC , was involved in ERK activation by the D 3 receptor in CHO cells. Because the reported IC 50 value of PKC inhibition by GF109203X is 5.8 M (Martiny- Baron et al., 1993) , it is unlikely that activation of this PKC isoform contributes sig- Fig. 6 . Inhibition of dopamine-stimulated MAPK activity by PTX and the MEK inhibitor PD98059. A, CHO-haD4.2 and CHO-haD2L cells were preincubated overnight in serum-free media alone, with PTX (200 ng/ml) or for 1 h with PD98059 (50 M) before stimulation with dopamine (1 M). After incubating with drugs for 5 min, phospho-MAPK(Thr202/ Tyr204) levels were measured in cell lysates by Western blotting. B, CHO-haD4.4 and CHO-haD2L were preincubated overnight in serumfree media alone (Control), with PTX (100 ng/ml), or for 1 h with vehicle (0.5% DMSO) or PD98059 (50 M) before stimulation with dopamine (1 M) for 5 min. ERK1/2 was immunoprecipitated from cell lysates and their activity was quantified with an in vitro kinase assay using MBP as a substrate. Data are presented as mean Ϯ S.D. (n ϭ 3). Groups with a statistically significant difference in kinase activity compared with control (dopamine-stimulated) values as determined by an unpaired t test are indicated by *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001. The PI3-kinase inhibitors wortmannin and LY294002 both attenuated dopamine-stimulated ERK activity by approximately 50%, as was previously observed with D 2S and D 3 cells expressed in CHO cells (Welsh et al., 1998; Cussac et al., 1999) . PI3-kinases are known to act upstream of Sos in G␤␥-mediated MAPK activation (Hawes et al., 1996) , but D 4 and D 2L do not use the same Ras-independent signaling pathway through PI3-kinase␥ and PKC that was described for lysophosphatidic acid receptors in CHO cells (Takeda et al., 1999 ), because we found that both dopamine receptors utilize Ras and a PKC other than PKC. However, we do not presently know the identity of the PI3-kinase involved in MAPK signaling by dopamine. Figure 15 shows a model of pathways leading from D 4 /D 2L to ERK activation based on our data. Grb2/Sos recruitment by phosphorylated PDGF receptor-␤ represents one mecha- (Duckworth and Cantley, 1997) . Both PLC-␥ and PI3-kinase can activate PKC⑀ after activation by the PDGF receptor (Moriya et al., 1996) , and GF109203X has been shown to fully block mitogenic signaling by PDGF receptor-␤ (Alimandi et al., 1997) . The mechanism by which G i/o trans-activates the PDGF receptor has not yet been identified.
It has recently emerged that the mechanism of MAPK activation by the ␤ 2 -adrenergic receptor seems to involve the formation of a complex between receptor, ␤-arrestin, dynamin, Src, and the EGF receptor . Activation of MEK requires dynamin-dependent endocytosis, where phosphorylation of dynamin by Src is required (Daaka et al., 1998) . This process may involve G protein-coupled receptor endocytosis, as seen with the ␤ 2 -adrenergic receptor, although internalization of the ␣ 2A -adrenergic receptor did not occur after EGF receptor trans-activation (Pierce et al., . In this regard, D 2L receptors are known to undergo agonist-dependent internalization in CHO cells (Itokawa et al., 1996) . Although Vickery and von Zastrow (1999) reported that D 2 receptors are internalized by a dynamin-independent mechanism, others have found that D 2 undergoes dynamindependent sequestration when coexpressed with GRK2 or GRK5 (Ito et al., 1999) . Because GRK2 is abundantly expressed in CHO cells, the ␤-arrestin/Src/dynamin-dependent mechanism of trans-activation may be involved. Although we do not observe agonist-stimulated internalization of the D 4 receptor (R. Vickery, M. von Zastrow, and H. H. M. Van Tol, unpublished observations), results with the ␣ 2 -adrenergic receptor have demonstrated that G protein-coupled receptor endocytosis is not required for dynamin-dependent transactivation .
Although ␤ 2 -adrenergic receptor trans-activation was independent of Ca 2ϩ , serotonin 5-HT 1A -dependent activation of ERK in CHO cells was dependent of Ca 2ϩ /calmodulin-and clathrin-dependent endocytosis (Della Rocca et al., 1999) . In this case, the Ca 2ϩ -dependent tyrosine kinase Pyk2 seems to mediate EGF receptor activation by bradykinin, presumably through activation of Src and downstream kinases (Blaukat et al., 1999) . Therefore, the Ca 2ϩ dependence of ERK signaling by D 4 and D 2L receptors may originate at the level of PDGF receptor endocytosis or Pyk2 activation.
The physiological role of dopamine receptor-mediated trans-activation is not fully understood; however, J. F. MacDonald (Dept. of Physiology, University of Toronto; unpublished observations) found that the D 4 receptor uses PDGF receptor-␤ trans-activation to block NMDA currents in hip- molpharm.aspetjournals.org pocampal neurons. In addition, the emergence of MAPK pathways as an element of G protein-coupled receptor signaling has also vastly increased the range of cellular processes that dopamine receptors may affect. Quinpirole was recently found to stimulate ERK phosphorylation in rat neurons in a PKC-and Ca 2ϩ -dependent manner (Yan et al., 1999) and dopamine D 2 -like receptor activation has been shown to contribute to long-term depression (LTD) in rat prefrontal cortex through a mechanism involving MAPK (Otani et al., 1999) . These finding suggest that dopamine D 2 -like receptor activation of MAPK pathways may play an important role in the brain, possibly through a mechanism involving trans-activation of receptor tyrosine kinases such as the PDGF receptor. 
